A Retrospective Analysis Comparing Treatment Response for Visceral Leishmaniasis-HIV Co-Infected Patients from the New World

Background: Visceral Leishmaniasis and Human Immunodeficiency Virus co-infection (VL-HIV) occurs mainly in risk groups for HIV/AIDS (youth adult males). These co-infected individuals have greater mortality and relapses rates compared to VL as they share similar immune pathogenic mechanisms. Interest in co-infection VL/HIV and the lack of data in the literature led the authors to a survey on the subject comparing outcomes in VL-HIV co-infected treated with different drugs anti-Leishmania used in Brazil, such that Pentavalent Antimoniate (MA), Amphotericin B deoxicolate (AmBd), and liposomal Amphotericin B (LAmB).